Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 4
Submit an article Journal homepage
410
Views
35
CrossRef citations to date
0
Altmetric
Reviews

Update on emerging drugs for cancer cachexia

Kate T Murphy The University of Melbourne, Department of Physiology, Basic and Clinical Myology Laboratory, Melbourne 3010, Australia
, PhD &
Gordon S Lynch The University of Melbourne, Department of Physiology, Basic and Clinical Myology Laboratory, Melbourne 3010, Australia +61 3 8344 0065; +61 3 8344 5818; [email protected]
, PhD
Pages 619-632 | Published online: 27 Oct 2009

Bibliography

  • Evans WJ, Morley JE, Argiles J, Cachexia: a new definition. Clin Nutr 2008;19:19
  • Curt GA, Breitbart W, Cella D, Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-60
  • Ahlberg K, Ekman T, Gaston-Johansson F, Assessment and management of cancer-related fatigue in adults. Lancet 2003;362:640-50
  • Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. Br Med J 1997;315:1219-22
  • Stewart GD, Skipworth RJ, Fearon KC. Cancer cachexia and fatigue. Clin Med 2006;6:140-3
  • Muscaritoli M, Bossola M, Aversa Z, Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006;42:31-41
  • DeBoer MD. Melanocortin interventions in cachexia: how soon from bench to bedside? Curr Opin Clin Nutr Metab Care 2007;10:457-62
  • Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003;4:686-94
  • Murray MJ, Murray AB. Anorexia of infection as a mechanism of host defense. Am J Clin Nutr 1979;32:593-6
  • Mantovani G, Maccio A, Mura L, Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78:554-61
  • Martin F, Santolaria F, Batista N, Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-6
  • Guttridge DC, Mayo MW, Madrid LV, NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363-6
  • Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-43
  • Holm E, Hagmuller E, Staedt U, Substrate balances across colonic carcinomas in humans. Cancer Res 1995;55:1373-8
  • Fredrix EW, Soeters PB, Wouters EF, Effect of different tumor types on resting energy expenditure. Cancer Res 1991;51:6138-41
  • Holroyde CP, Skutches CL, Boden G, Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 1984;44:5910-3
  • Shaw JH, Wolfe RR. Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion, parenteral feeding, and surgical resection. Surgery 1987;101:181-91
  • Noguchi Y, Yoshikawa T, Marat D, Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-alpha expression in skeletal muscle. Biochem Biophys Res Commun 1998;253:887-92
  • de Alvaro C, Teruel T, Hernandez R, Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004;279:17070-8
  • Rydén M, Agustsson T, Laurencikiene J, Lipolysis-not inflammation, cell death, or lipogenesis-is involved in adipose tissue loss in cancer cachexia. Cancer 2008;113:1695-704
  • Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987;47:5919-23
  • Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410
  • Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997;76:1035-40
  • Emery PW, Edwards RH, Rennie MJ, Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br Med J (Clin Res Ed) 1984;289:584-6
  • Emery PW, Lovell L, Rennie MJ. Protein synthesis measured in vivo in muscle and liver of cachectic tumor-bearing mice. Cancer Res 1984;44:2779-84
  • Wyke SM, Tisdale MJ. NF-κB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 2005;92:711-21
  • Cai D, Frantz JD, Tawa NEJr, IKKbeta/NF-κB activation causes severe muscle wasting in mice. Cell 2004;119:285-98
  • McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
  • Costelli P, Muscaritoli M, Bonetto A, Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008;38:531-8
  • Langley B, Thomas M, Bishop A, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002;277:49831-40
  • Amirouche A, Durieux AC, Banzet S, Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009;150:286-94
  • McFarlane C, Plummer E, Thomas M, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006;209:501-14
  • Dinh DT, Frauman AG, Somers GR, Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 2002;196:213-9
  • Russell ST, Sanders PM, Tisdale MJ. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett 2006;231:290-4
  • Russell ST, Wyke SM, Tisdale MJ. Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal 2006;18:1087-96
  • Burniston JG, Saini A, Tan LB, Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 2005;90:755-61
  • Zhang L, Du J, Hu Z, IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009;20:604-12
  • Argilés JM, Lépez-Soriano FJ, Busquets S. Emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2007;12:555-70
  • Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: Amercian Cancer Society; 2007
  • Fox KM, Brooks JM, Gandra SR, Estimation of cachexia among cancer patients based on four definitions. J Oncol 2009;2009:693458
  • Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001;61:1432-8
  • Nicholson JR, Kohler G, Schaerer F, Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 2006;317:771-7
  • Markison S, Foster AC, Chen C, The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005;146:2766-73
  • Dass NB, Munonyara M, Bassil AK, Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 2003;120:443-53
  • Ejskjaer N, Vestergaard ET, Hellstrom PM, Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009;29:1179-87
  • Wren AM, Seal LJ, Cohen MA, Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992
  • Neary NM, Small CJ, Wren AM, Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:2832-6
  • Wicek A, Niemczyk S, Szczechowska E, AKL-0707 GHRH super analogue treatment of malnutrition in patients with chronic kidney disease XIV International Congress on Nutrition and Metabolism in Renal Disease. Marseilles J Renal Nutr 2008;18:S26
  • Broglio F, Boutignon F, Benso A, EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J Endocrinol Invest 2002;25:RC26-8
  • Piccoli F, Degen L, MacLean C, Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab 2007;92:1814-20
  • Lasseter KC, Shaughnessy L, Cummings D, Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2008;48:193-202
  • Thomas H, Berthiaume N, Kneebone E, The ghrelin receptor agonist TZP-101 is a potent anti-tumour-cachexia agent in the human G361 melanoma mouse xenograft model. 20th EORTC-NCI-AACR Symp Mol Target Cancer Ther (Geneva) 2008 : abstract 338
  • Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007;12:594-600
  • Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009;19:267-73
  • Garcia J, Boccia RV, Graham C, A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):9133
  • Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27:360-9
  • Yeh SS, Lovitt S, Schuster MW. Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly. J Nutr Health Aging 2009;13:448-54
  • Lesniak W, Bala M, Jaeschke R, Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome-a systematic review and meta-analysis. Pol Arch Med Wewn 2008;118:636-44
  • Jatoi A, Windschitl HE, Loprinzi CL, Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-73
  • Jatoi A, Rowland K, Loprinzi CL, An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22:2469-76
  • Loprinzi CL, Kugler JW, Sloan JA, Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-306
  • Par Pharmaceuticals, Inc. Megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2. Drugs R D 2007;8:403-6
  • Cilla DD, Gutierrez JL, Femia RA, A pilot study comparing megestrol acetate concentrated suspension (MA-CS) to megestrol acetate oral auspension (MA-OS) on weight gain and body composition in patients with HIV-associated unintended weight loss (UWL). ASH Annual Meeting Abstracts 2005;106:1433
  • Klein TW, Lane B, Newton CA, The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000;225:1-8
  • Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971;231:260-1
  • Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997;126:791-8
  • Plasse TF, Gorter RW, Krasnow SH, Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695-700
  • Beal JE, Olson R, Laubenstein L, Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97
  • Beal JE, Olson R, Lefkowitz L, Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14:7-14
  • Lazzarino DA, de Diego M, Hirschman SZ, IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes. Cytokine 2001;14:234-9
  • D'Olimpio JT, Hirschman SZ, Shtemer Z, Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase 1/11 clinical trial. J Clin Oncol (Meeting Abstracts) 2004;22:8087
  • D'Olimpio JT, Chasen MR, Sharma R, Phase II study of AVR118 in the management of cancer related anorexia/cachexia. J Clin Oncol 2009;27(Suppl):abstract e20631
  • Moreira AL, Sampaio EP, Zmuidzinas A, Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80
  • D'Amato RJ, Loughnan MS, Flynn E, Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
  • Keifer JA, Guttridge DC, Ashburner BP, Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001;276:22382-7
  • Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004;110:260-5
  • Liu KH, Liao LM, Ro LS, Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. Surgery 2008;143:375-83
  • Khan ZH, Simpson EJ, Cole AT, Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003;17:677-82
  • Gordon JN, Trebble TM, Ellis RD, Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled. trial Gut 2005;54:540-5
  • Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol 2004;15:1151-60
  • Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9
  • Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
  • Jatoi A, Dakhil SR, Nguyen PL, A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396-403
  • Monk JP, Phillips G, Waite R, Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24:1852-9
  • Wiedenmann B, Malfertheiner P, Friess H, A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25
  • Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004;111:592-5
  • van Zaanen HC, Lokhorst HM, Aarden LA, Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998;102:783-90
  • Clarke SJ, Smith JT, Gebbie C, A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol 2009;27:3025
  • Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008;88:729-67
  • Busquets S, Figueras MT, Fuster G, Anticachectic effects of formoterol: A drug for potential treatment of muscle wasting. Cancer Res 2004;64:6725-31
  • Ryall JG, Schertzer JD, Murphy KT, Chronic beta2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity. Am J Physiol 2008;294:H2587-95
  • Chance WT, Cao LQ, Zhang FS, Clenbuterol treatment increases muscle mass and protein content of tumor-bearing rats maintained on total parenteral nutrition. JPEN J Parenter Enteral Nutr 1991;15:530-5
  • Chen WS, Wei SJ, Liu JM, Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001;91:894-9
  • Masur K, Niggemann B, Zanker KS, Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-9
  • Benish M, Bartal I, Goldfarb Y, Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008;15:2042-52
  • Lynch GS. Update on emerging drugs for sarcopenia - age-related muscle wasting. Expert Opin Emerg Drugs 2008;13:655-73
  • Morton RAJ, Barnette KG, Hancock ML, et al. The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia. Endocrine Society Annual Meeting; Washington; 2009. p. S21-1
  • Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004;64:725-50
  • Mwamburi DM, Gerrior J, Wilson IB, Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clin Infect Dis 2004;38:895-902
  • Boughton B. Drug increases lean tissue mass in patients with cancer. Lancet Oncol 2003;4:135
  • Von Roenn JH, Tchekmedyian S, Hoffman RM, Safety of oxandrolone in cancer-related weight loss. Proc Am Soc Clin Oncol 2003;22:abstract 3013
  • Liu CM, Yang Z, Liu CW, Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 2008;15:155-60
  • Wagner KR, Fleckenstein JL, Amato AA, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;11:11
  • Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509-16
  • Wei Y, Sowers JR, Nistala R, Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281:35137-46
  • Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29:1675-84
  • Yamaguchi K, Ura N, Murakami H, Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle. Hypertens Res 2005;28:773-8
  • Molteni A, Heffelfinger S, Moulder JE, Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem 2006;6:451-60
  • Henriksen EJ, Jacob S, Kinnick TR, Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001;38:884-90
  • Neo JH, Malcontenti-Wilson C, Muralidharan V, Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007;22:577-84
  • Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005;93:425-34
  • Onder G, Penninx BW, Balkrishnan R, Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002;359:926-30
  • Ark's Vitor sends mixed message in cancer cachexia. Scrip Daily Online 18 January 2006. Available from: http://www.scripnews.com
  • Wigmore SJ, Fearon KC, Maingay JP, Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 1997;92:215-21
  • Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991;41:103-7
  • Tisdale MJ. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 1996;12:S31-3
  • Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991;51:6089-93
  • Whitehouse AS, Smith HJ, Drake JL, Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001;61:3604-9
  • Smith HJ, Greenberg NA, Tisdale MJ. Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice. Br J Cancer 2004;91:408-12
  • Costelli P, Llovera M, Lopez-Soriano J, Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Lett 1995;97:25-32
  • Bruera E, Strasser F, Palmer JL, Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003;21:129-34
  • Fearon KC, Barber MD, Moses AG, Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7
  • Barber MD, Ross JA, Voss AC, The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.